The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies.
Satoshi Yuki
No relevant relationships to disclose
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult
Hiraku Fukushima
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Yoshimitsu Kobayashi
No relevant relationships to disclose
Kazuaki Harada
No relevant relationships to disclose
Toraji Amano
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Mineo Kudo
No relevant relationships to disclose
Miki Tateyama
No relevant relationships to disclose
Kazuteru Hatanaka
No relevant relationships to disclose
Soh Saitoh
No relevant relationships to disclose
Takuto Miyagishima
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Yasuyuki Kawamoto
No relevant relationships to disclose
Tomofumi Takagi
No relevant relationships to disclose
Ichiro Iwanaga
No relevant relationships to disclose
Kencho Miyashita
No relevant relationships to disclose
Manabu Onodera
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck; Otsuka; Synergy International; Taiho Pharmaceutical; Yakult